Common Contracts
6 similar Common Stock Purchase Warrant contracts by Cidara Therapeutics, Inc., Ayala Pharmaceuticals, Inc., Q BioMed Inc., others
COMMON STOCK PURCHASE WARRANT AYALA PHARMACEUTICALS, INC.Common Stock Purchase Warrant • March 5th, 2024 • Ayala Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ISRAEL BIOTECH FUND I, L.P. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November 17, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on November 17, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from AYALA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), up to 2,250,000 shares of its common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
FORM OF COMMON STOCK PURCHASE WARRANT TD HOLDINGS, INC.Common Stock Purchase Warrant • August 27th, 2021 • TD Holdings, Inc. • National commercial banks
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the date that is the five (5) year anniversary of the Issuance Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from TD Holdings, Inc., a Delaware corporation (the “Company”), up to [_____] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. This Warrant is one of the warrants to purchase shares of Common Stock issued pursuant to that certain Securities Purchase Agreement (the “Purchase Agreement”) dated as of August [ ], 2021 among the Company and the purchasers signatory thereto, as amended from time to time.
COMMON STOCK PURCHASE WARRANT SINO-GLOBAL SHIPPING AMERICA, LTD.Common Stock Purchase Warrant • November 4th, 2020 • Sino-Global Shipping America, Ltd. • Arrangement of transportation of freight & cargo
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 3, 2021 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 3, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sino-Global Shipping America, Ltd., a Virginia corporation (the “Company”), up to 120,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. This Warrant is one of the warrants to purchase shares of Common Stock issued pursuant to that certain Securities Purchase Agreement (the “Purchase Agreement”) dated as of [ ], 2020 among the Company and the purchasers signatory thereto, as amended from time to time.
COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • May 21st, 2018 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _______________ (the “Initial Exercise Date”) and on or prior to the Termination Date but not thereafter, to subscribe for and purchase from Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder), the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • May 21st, 2018 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May ___, 2018 (the “Initial Exercise Date”) and on or prior to the Termination Date but not thereafter, to subscribe for and purchase from Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder), the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT Q BIOMED INC.Common Stock Purchase Warrant • January 10th, 2018 • Q BioMed Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ________, 2018 (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Q BioMed Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
